Elotuzumab Enhances CD16-Independent NK Cell-Mediated Cytotoxicity against Myeloma Cells by Upregulating Several NK Cell-Enhancing Genes

Figure 6

qPCR analysis of the relative mRNA expression of GZMB, PRF1, TNF-α (a), CRTAM, TNFRSF9, EAT-2, IL-1α, HSPA6, FOXP3, T-BET, and EOMES and (b) in NK-92MI (E, CD16-independent) cells pretreated without or with Elo (10 μg/mL, 37°C, 1 hr), and then cocultured with K562, U266, RPMI 8226 (RPMI), and MM.1S target (T) cells (E : T ratio of 10 : 1) for 1, 2, 4, and 24 hr. Gene expression levels are expressed as the ratio of the expression in the group pretreated with Elo to that in the group pretreated without Elo (black bar). The Elo-pretreated groups are shown at the time points of 1 hr (red), 2 hr (orange), 4 hr (blue), and 24 hr (green). Results are presented as mean ± SD of four independent experiments for every target cell. , , and .

(a)

(b)